Gilead Sciences, Inc. (GILD)'s Mixed Quarter Draws Divergent Analyst Views

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best blue-chip stocks to buy now. On November 3, Bernstein SocGen Group reiterated its “Outperform” rating on Gilead Sciences, Inc. (NASDAQ: GILD), setting a price target of $135. The firm highlighted the company’s solid third-quarter performance and noted continued strength in HIV therapies and emerging treatments as reasons for optimism about future growth.

Earlier, on October 31, Maxim Group analyst Michael Okunewitch maintained a neutral stance, reaffirming a Hold rating. He acknowledged strong HIV sales, particularly from Biktarvy and Yeztugo. However, he raised concerns over limited growth elsewhere, with the oncology unit facing competitive pressures and liver disease still being a smaller contributor. He concluded that Gilead’s reliance on HIV treatments and valuations in line with peers warranted caution.

On October 30, Gilead had reported third‑quarter revenues of $7.8 billion, up 3% from the prior year. Product sales declined 2% to $7.3 billion, primarily due to weaker demand for Veklury and Cell Therapy, although the HIV and liver disease portfolios provided a lift. Earnings per share rose to $2.43 from $1.00 a year earlier, aided by the absence of large impairment charges and a $400 million boost from other revenues.

Gilead has lifted its full‑year outlook, projecting revenue between $28.4 billion and $28.7 billion, slightly higher than its earlier range of $28.3 billion to $28.7 billion. The company now expects earnings per share to come in between $8.05 and $8.25, compared with the prior forecast of $7.95 to $8.25.

Based in Foster City, California, Gilead Sciences (NASDAQ:GILD) is a biopharmaceutical firm known for developing treatments for serious illnesses, including HIV, viral hepatitis, and cancer.

While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: Top 9 Undervalued Asset Management Stocks to Buy and 13 Best AI Stocks to Buy Under $20.

Disclosure: None. This article is originally published at Insider Monkey.